Restoration of soluble CD146 in patients with Crohn's disease treated with the TNF-alpha antagonist infliximab.
Reumaux
Dominique
D
Bardin
Nathalie
N
Colombel
Jean-Frédéric
JF
Dignat-George
Françoise
F
Duthilleul
Patrick
P
Vermeire
Séverine
S
D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D015415:Biomarkers / Q000378:metabolism; D051929:CD146 Antigen / Q000187:drug effects / Q000378:metabolism*; D003424:Crohn Disease / Q000188:drug therapy / Q000276:immunology / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000069285:Infliximab; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D015415:Biomarkers; D051929:CD146 Antigen; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab